New and Improved Devices Add More Therapeutic Options for Treatment of MigraineNovember 18, 2022Headache & Migraine
Meta-analysis evaluates safety and efficacy of cinnarizine in migraineOctober 23, 2022Headache & Migraine
Risk for inpatient constipation similar with erenumab and other anti-CGRP mAb in migraineOctober 23, 2022Headache & Migraine
Preventive treatment improves cognition and QoL in patients with chronic migraineOctober 23, 2022Headache & Migraine
Changes in gastrointestinal motility with galcanezumab and erenumab in episodic migraineOctober 23, 2022Headache & Migraine
Association between CGRP-LI levels and migraine treatment outcomes with erenumab October 23, 2022Headache & Migraine
Benefit-risk profiles of lasmiditan, rimegepant, and ubrogepant for acute treatment of migraineOctober 23, 2022Headache & Migraine
Overlapping initial symptoms demand careful differential diagnosis of migraine and ischemic strokeOctober 23, 2022Headache & Migraine
Real-world efficacy of galcanezumab in high frequency episodic and chronic migraineOctober 23, 2022Headache & Migraine
Meta-analysis corroborates evidence on efficacy of onabotulinumtoxinA for chronic migraineOctober 23, 2022Headache & Migraine
Anti-CGRP receptor mAb increase blood pressure in patients with migraineOctober 23, 2022Headache & Migraine
Commentary: Menstruation, sleep, and visual disturbances in migraine, October 2022October 4, 2022Headache & Migraine
Real-world efficacy and safety of anti-CGRP drugs in drug-resistant chronic migraineSeptember 19, 2022Headache & Migraine
